AU2020279253A1 - KRAS G12C inhibitors and uses thereof - Google Patents
KRAS G12C inhibitors and uses thereof Download PDFInfo
- Publication number
- AU2020279253A1 AU2020279253A1 AU2020279253A AU2020279253A AU2020279253A1 AU 2020279253 A1 AU2020279253 A1 AU 2020279253A1 AU 2020279253 A AU2020279253 A AU 2020279253A AU 2020279253 A AU2020279253 A AU 2020279253A AU 2020279253 A1 AU2020279253 A1 AU 2020279253A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- independently
- proviso
- alkyl
- heteroatoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OMDFBBCMQSCPHP-OQLLNIDSSA-N CN(C)C/C=C/C(N(CC1)C(CC#N)CN1c1nc(OCC(C2)N(C)CC2[F]c2c(CCC3(C4)Cc5nc(OCC6N(C)CCC6)nc(N(CC6)CC(CC#N)N6C(C(F)=C)=O)c5CC3)c4ccc2)nc2c1CCC(CC1)(Cc3c1c(F)ccc3)C2)=O Chemical compound CN(C)C/C=C/C(N(CC1)C(CC#N)CN1c1nc(OCC(C2)N(C)CC2[F]c2c(CCC3(C4)Cc5nc(OCC6N(C)CCC6)nc(N(CC6)CC(CC#N)N6C(C(F)=C)=O)c5CC3)c4ccc2)nc2c1CCC(CC1)(Cc3c1c(F)ccc3)C2)=O OMDFBBCMQSCPHP-OQLLNIDSSA-N 0.000 description 1
- PUNJBTLQTKSVBE-UHFFFAOYSA-N CN1C(COc2nc(CC3(CC4)Cc5cccc([F]C6CN(C)C(COc7nc(N(CC8)CC(COC)N8C(C(F)=C)=O)c(CCC(CC8)(Cc9c8c(F)ccc9)C8)c8n7)C6)c5CC3)c4c(N(CC3)CC(COC)N3C(C=C)=O)n2)CCC1 Chemical compound CN1C(COc2nc(CC3(CC4)Cc5cccc([F]C6CN(C)C(COc7nc(N(CC8)CC(COC)N8C(C(F)=C)=O)c(CCC(CC8)(Cc9c8c(F)ccc9)C8)c8n7)C6)c5CC3)c4c(N(CC3)CC(COC)N3C(C=C)=O)n2)CCC1 PUNJBTLQTKSVBE-UHFFFAOYSA-N 0.000 description 1
- BILLNEAWABDLLI-OMYYVPRQSA-N CN1[C@H](COc2nc(C[C@@](CC3)(CC4)Cc5c3cc(C3CN(C)[C@H](COc6nc(C[C@@](CC7)(CC8)Cc9c7cccc9)c8c(N(CC7)C[C@H](CC#N)N7C(C(F)=C)=O)n6)C3)cc5)c4c(N(CC3)C[C@H](CC#N)N3C(C=C)=O)n2)CCC1 Chemical compound CN1[C@H](COc2nc(C[C@@](CC3)(CC4)Cc5c3cc(C3CN(C)[C@H](COc6nc(C[C@@](CC7)(CC8)Cc9c7cccc9)c8c(N(CC7)C[C@H](CC#N)N7C(C(F)=C)=O)n6)C3)cc5)c4c(N(CC3)C[C@H](CC#N)N3C(C=C)=O)n2)CCC1 BILLNEAWABDLLI-OMYYVPRQSA-N 0.000 description 1
- GKSBWUVVYZTRMJ-JHQWEEBLSA-N CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(CC[C@@](C3)(C4)CN(C)c5c3cc(C3CN(C)[C@H](COc6nc(C[C@]7(CC8)Cc9cccc(F)c9CC7)c8c(N(CC7)C[C@H](CC#N)N7C(C=C)=O)n6)C3)cc5)c4n2)CCC1 Chemical compound CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(CC[C@@](C3)(C4)CN(C)c5c3cc(C3CN(C)[C@H](COc6nc(C[C@]7(CC8)Cc9cccc(F)c9CC7)c8c(N(CC7)C[C@H](CC#N)N7C(C=C)=O)n6)C3)cc5)c4n2)CCC1 GKSBWUVVYZTRMJ-JHQWEEBLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850289P | 2019-05-20 | 2019-05-20 | |
| US62/850,289 | 2019-05-20 | ||
| PCT/US2020/033816 WO2020236940A1 (en) | 2019-05-20 | 2020-05-20 | Kras g12c inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020279253A1 true AU2020279253A1 (en) | 2021-12-16 |
Family
ID=73458223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020279253A Abandoned AU2020279253A1 (en) | 2019-05-20 | 2020-05-20 | KRAS G12C inhibitors and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220227738A1 (enExample) |
| EP (1) | EP3972978A4 (enExample) |
| JP (1) | JP7502337B2 (enExample) |
| KR (1) | KR20220038289A (enExample) |
| CN (1) | CN114096544B (enExample) |
| AU (1) | AU2020279253A1 (enExample) |
| BR (1) | BR112021023359A2 (enExample) |
| CA (1) | CA3141604A1 (enExample) |
| IL (1) | IL288200A (enExample) |
| MX (1) | MX2021014177A (enExample) |
| SG (1) | SG11202112790SA (enExample) |
| WO (1) | WO2020236940A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| CN114630832A (zh) * | 2019-11-15 | 2022-06-14 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2021139748A1 (en) * | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| JP7808058B2 (ja) | 2020-06-02 | 2026-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
| WO2022040469A1 (en) * | 2020-08-19 | 2022-02-24 | The Trustees Of The Stevens Institute Of Technology | Spiro compounds as kras inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114685502A (zh) | 2020-12-25 | 2022-07-01 | 由理生物医药（上海）有限公司 | 作为kras-g12c抑制剂的螺环类化合物 |
| CN114805311B (zh) * | 2021-01-21 | 2024-10-29 | 苏州亚盛药业有限公司 | 螺环茚 |
| WO2022240971A2 (en) * | 2021-05-11 | 2022-11-17 | 1200 Pharma Llc | Kras g12d inhibitors and uses thereof |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| CA3237274A1 (en) * | 2021-11-09 | 2023-05-19 | 1200 Pharma Llc | Select kras g12c inhibitors and uses thereof |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099608A1 (en) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CA3243798A1 (en) * | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025237091A1 (zh) * | 2024-05-17 | 2025-11-20 | 中山优理生物医药有限公司 | 螺环类化合物的制备方法及其中间体 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US20100298289A1 (en) * | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| EP3055290B1 (en) * | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2898765T3 (es) * | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| KR102444509B1 (ko) * | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| US20190134056A1 (en) * | 2017-03-10 | 2019-05-09 | The Trustees Of The Stevens Institute Of Technolog | K-ras mutations and antagonists |
| CN110869357A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| US10745385B2 (en) * | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| EA201992780A1 (ru) * | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| TW201942116A (zh) * | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
| US11096939B2 (en) * | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (es) * | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| AU2019320945C1 (en) * | 2018-08-16 | 2021-09-30 | F. Hoffmann-La Roche Ag | Fused ring compounds |
| WO2021139748A1 (en) * | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| WO2022040469A1 (en) * | 2020-08-19 | 2022-02-24 | The Trustees Of The Stevens Institute Of Technology | Spiro compounds as kras inhibitors |
-
2020
- 2020-05-20 JP JP2021568865A patent/JP7502337B2/ja active Active
- 2020-05-20 MX MX2021014177A patent/MX2021014177A/es unknown
- 2020-05-20 EP EP20810811.8A patent/EP3972978A4/en active Pending
- 2020-05-20 US US17/612,972 patent/US20220227738A1/en active Pending
- 2020-05-20 AU AU2020279253A patent/AU2020279253A1/en not_active Abandoned
- 2020-05-20 SG SG11202112790SA patent/SG11202112790SA/en unknown
- 2020-05-20 BR BR112021023359A patent/BR112021023359A2/pt unknown
- 2020-05-20 WO PCT/US2020/033816 patent/WO2020236940A1/en not_active Ceased
- 2020-05-20 KR KR1020217041514A patent/KR20220038289A/ko not_active Ceased
- 2020-05-20 CN CN202080052231.0A patent/CN114096544B/zh active Active
- 2020-05-20 CA CA3141604A patent/CA3141604A1/en active Pending
-
2021
- 2021-11-17 IL IL288200A patent/IL288200A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220227738A1 (en) | 2022-07-21 |
| SG11202112790SA (en) | 2021-12-30 |
| IL288200A (en) | 2022-01-01 |
| EP3972978A1 (en) | 2022-03-30 |
| BR112021023359A2 (pt) | 2022-02-01 |
| CN114096544A (zh) | 2022-02-25 |
| CA3141604A1 (en) | 2020-11-26 |
| EP3972978A4 (en) | 2023-04-26 |
| CN114096544B (zh) | 2025-08-12 |
| JP2022533398A (ja) | 2022-07-22 |
| MX2021014177A (es) | 2022-04-25 |
| KR20220038289A (ko) | 2022-03-28 |
| WO2020236940A1 (en) | 2020-11-26 |
| JP7502337B2 (ja) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114096544B (zh) | Kras g12c抑制剂及其用途 | |
| WO2022115439A1 (en) | Kras g12c inhibitors and uses thereof | |
| JP7041070B2 (ja) | Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物 | |
| JP2023528903A (ja) | Ｋｒａｓ ｇ１２ｃタンパク質阻害剤およびその使用 | |
| TWI618698B (zh) | 新型嘧啶和吡啶類化合物及其用途 | |
| JP2017178968A (ja) | 化合物、その医薬組成物、及び癌治療用のｉｄｈ１突然変異阻害薬としてのその使用 | |
| AU2011344270A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| WO2025000265A1 (en) | Heterocyclic compounds usefull as sos1 inhibitor | |
| ES2984158T3 (es) | Inhibidores y moduladores de WDR5 | |
| WO2023101981A1 (en) | Spirocyclic inhibitors of apol1 and methods of using same | |
| AU2020245480A1 (en) | PRMT5 inhibitors and uses thereof | |
| WO2023125737A1 (en) | Heterocyclic compounds and use thereof | |
| CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 | |
| WO2024102784A1 (en) | Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof | |
| WO2023040998A1 (en) | A cyclin-dependent kinase inhibitor | |
| WO2023046128A1 (en) | A cyclin-dependent kinase inhibitor | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| WO2022236101A1 (en) | Wdr5 inhibitors and modulators | |
| WO2021067827A1 (en) | Mcl1 inhibitors and uses thereof | |
| RU2835080C1 (ru) | Новый ингибитор aurora киназы и его применение | |
| CN114149410B (zh) | 吡啶并环类化合物及其制备方法和用途 | |
| WO2022216946A1 (en) | Mcl1 inhibitors and uses thereof | |
| HK40074494B (zh) | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 | |
| HK40090980A (zh) | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 | |
| HK40002420A (zh) | 作为ehmt1和ehmt2抑制剂的胺取代的芳基或杂芳基化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |